H2 Medical Technologies unveils first hydrogen-based device for Alzheimer’s trials

Prototype inhaler for Alzheimer's therapy: ©H2 Medical Technologies

H2 Medical Technologies, part of the H2 Global Group, has developed what it says is the world’s first functional hydrogen-based therapy medical device prototype for clinical trials targeting Alzheimer’s disease.

The company announced the breakthrough, saying the device is designed to both prevent and treat the neurodegenerative condition, which affects more than 6.5 million Americans and 50 million people worldwide. The World Health Organization projects those numbers could triple by 2050.

“This is not another experiment — it is the first technology in the world with the potential to prevent Alzheimer’s disease before it even starts, while supporting those already affected,” said David Marsalek, founder and CEO of H2 Global Group. He added that a new clinical trial is expected to further confirm the therapy’s effectiveness.

The device will be presented at LSI Europe 2025 in London, one of the leading MedTech and HealthTech conferences. The technology is based on more than three decades of research led by molecular hydrogen pioneer Shigeo Ohta, co-founder of H2 Global Group.

Although the company’s immediate focus is Alzheimer’s, executives said the therapy could also apply to brain regeneration, neurological disorders, and healthy aging. Beyond the clinical device, H2 Global Group has launched hydrogen-based consumer health products and is the only certified manufacturer allowed to use hydrogen-based medical devices in veterinary care.

Hydrogen-based treatments are already being adopted by wellness centers, rehabilitation clinics, dental practices, and sports organizations across Europe, according to the company.

Advances in Alzheimer’s research and brain health technologies

The race to address Alzheimer’s disease has accelerated in recent years, as researchers explore a wide range of approaches to prevention, early detection, and treatment. While traditional drug development has often centered on targeting amyloid plaques in the brain, many new avenues of research are expanding beyond this single focus.

One area drawing attention is the use of noninvasive medical devices that aim to influence brain health through mechanisms such as light, sound, or electrical stimulation. These technologies are being studied for their potential to enhance cognition, slow disease progression, and even promote neuroplasticity.

Meanwhile, scientists are also advancing biomarker research to enable earlier and more accurate diagnosis. Blood-based tests, imaging tools, and genetic screening methods are being refined to detect Alzheimer’s in its earliest stages, when interventions may have the greatest impact.

Lifestyle-based interventions are also part of the emerging landscape. Clinical studies are exploring how diet, exercise, sleep, and stress reduction can reduce risk or delay the onset of dementia. These findings are increasingly shaping public health recommendations, reflecting the idea that prevention may be as important as treatment.

Beyond Alzheimer’s, breakthroughs in brain health research are also extending to conditions such as Parkinson’s disease, traumatic brain injury, and age-related cognitive decline. Advances in regenerative medicine and microbiome research are beginning to overlap with neuroscience, suggesting new pathways for supporting brain resilience across the lifespan.

Together, these innovations signal a broader shift in brain health strategies — one that blends medical devices, pharmaceuticals, lifestyle approaches, and digital health tools to tackle one of the most pressing health challenges of the 21st century.